Clinical Trial: Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL

Official Title: A Multicenter, Open Label Study of QRX003 Lotion in Subjects With Netherton Syndrome

Brief Summary: To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome

Detailed Summary:
Sponsor: Quoin Pharmaceuticals

Current Primary Outcome: Proportion of subjects with 1-point reduction on the Investigator's Global Assessment (IGA) from Baseline.
The IGA assesses overall severity of a subject's NS based on a 5-point scale where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.

Original Primary Outcome: Proportion of subjects with 1-point reduction on the Investigator's Global Assessment (IGA) from Baseline.
The IGA assesses overall severity of a subject's NS based on a 5-point scale where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Quoin Pharmaceuticals

Dates:
Date Received: March 16, 2023
Date Started: March 14, 2023
Date Completion: March 14, 2023
Last Updated: November 14, 2023
Last Verified: November 01, 2023